Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors
OBJECTIVES: I. Evaluate the toxicity of allogeneic cytotoxic T lymphocytes (CTL) when
repeatedly instilled directly into the brain to treat recurrent primary brain tumors. II.
Evaluate the response produced by allogeneic CTL and interleukin-2. III. Correlate CTL
surface phenotype and degree of patient/donor HLA mismatch to response and toxicity.
OUTLINE: Surgery plus Biological Response Modifier Therapy. Tumor resection; plus
intracavitary cytotoxic T lymphocytes, CTL; intracavitary Interleukin-2 (Chiron), IL-2,
NSC-373364. CTL are generated in vitro by mixing irradiated patient lymphocytes (cultured
with IL-2 and Monoclonal Antibody OKT 3, MOAB OKT 3, NSC-618843) with allogeneic lymphocytes
and culturing the mixture with IL-2.
PROJECTED ACCRUAL: 10 patients will be treated. If severe toxicity occurs in the first 5
patients, the study will close.
Primary Purpose: Treatment
Kevin O. Lillehei, MD
University of Colorado, Denver
United States: Federal Government
|University of Colorado Cancer Center||Denver, Colorado 80262|
|Veterans Affairs Medical Center - Denver||Denver, Colorado 80220|
|Children's Health Center||Denver, Colorado 80218|